Global Acne Market 2014-2018

Global Acne Market 2014-2018

Category : Healthcare
Published On : November  2014
Pages : 72


------------ Or -------------
About Acne
Acne is one of the common dermatological disorders. Acne, or acne vulgaris is an inflammatory disorder of the skin which affects people of almost all age groups. The exact etiology of acne is not fully understood. Although acne does not present a serious threat to health, severe acne can not only be painful, but also affect a patient’s quality of life. Topical medications, oral medications, or a combination of all are some of the treatment options available for acne.

TechNavio's analysts forecast the Global Acne market to grow at a CAGR of 4.07 percent over the period 2013-2018.
Covered in this Report
The Global Acne market can be divided into seven segments: Antibiotics, Anti-Inflammatories, Antimicrobials, Combination Medications, Hormonal Agents, Oral Retinoid, and Topical Retinoid. This report covers the present scenario and the growth prospects of the Global Acne market for the period 2013–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs and topical creams used in the treatment of acne that are available in the market.
TechNavio's report, the Global Acne Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Acne market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA        
Key Vendors
• Actavis 
• Allergen 
• Galderma 
• Stiefel Laboratories 
• Valeant Pharmaceuticals International 
Other Prominent Vendors
• Andro Science 
• Bayer 
• Cipher Pharmaceuticals 
• Cosmo Pharmaceuticals 
• Elorac 
• Foamix Pharmaceuticals 
• Helix BioMedix 
• Hygeia Therapeutics 
• J&J 
• Mylan Pharmaceuticals 
• NanoBio 
• NovaLead Pharma 
• F. Hoffmann-La Roche

Market Driver
• Significant Unmet Needs 
• For a full, detailed list, view our report
Market Challenge
• High Cost of Acne Drugs
• For a full, detailed list, view our report
Market Trend
• Increased Focus on Combination Therapies  
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. Implications of Acne
07.1 Five Forces Analysis
08. Types and Characteristics of Acne
09. Competitive Assessment of Marketed Products
10. Rate of Incidence and Prevalence
10.1.1 US
10.1.2 UK
11. Market Segmentation by Category
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Actavis plc
21.1.1 Key Facts
21.1.2 Business Description
21.1.3 Business Segmentation
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Information
21.1.8 SWOT Analysis
21.2 Allergan Inc.
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Revenue by Business Segmentation
21.2.5 Revenue Comparison 2011-2013
21.2.6 Revenue by Geographical Segmentation
21.2.7 Business Strategy
21.2.8 Key Developments
21.2.9 SWOT Analysis
21.3 Galderma
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Product Segmentation by Revenue 2013
21.3.4 Geographical Segmentation by Revenue 2013
21.3.5 Business Strategy
21.3.6 Recent Developments
21.3.7 SWOT Analysis
21.4 Stiefel Laboratories
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Product Segmentation
21.4.4 Geographical Segmentation by Revenue 2013
21.4.5 Business Strategy
21.4.6 Recent Developments
21.4.7 SWOT Analysis
21.5 Valeant Pharmaceuticals International Inc.
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Sales by Geography
21.5.6 Business Strategy
21.5.7 Key Developments
21.6 SWOT Analysis

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Acne Market 2013-2018 (US$ billion)
Exhibit 4: Global Acne Market Segmentation by Category
Exhibit 5: Global Acne Market by Geographical Segmentation 2013
Exhibit 6: Allergen Sales by Portfolio 2012
Exhibit 7: Galderma Sales by Therapeutic Area 2012
Exhibit 8: Global Acne marketBusiness Segmentation 2013
Exhibit 9: Global Acne market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 10: Actavis Plc: Sales by Geography (in US$ million)
Exhibit 11: Allergan Inc.: Business Segmentation
Exhibit 12: Allergan Inc.: Revenue by Business Segmentation 2013
Exhibit 13: Allergan Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ billion)
Exhibit 14: Allergan Inc.: Revenue by Geographical Segmentation 2013
Exhibit 15: Galderma: Product Segmentation by Revenue 2013
Exhibit 16: Galderma: Geographical Segmentation by Revenue 2013
Exhibit 17: Stiefel Laboratories: Product Segmentation 2013
Exhibit 18: Stiefel Laboratories: Geographical Segmentation by Revenue 2013
Exhibit 19: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2013
Exhibit 20: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 21: Valeant Pharmaceuticals International Inc.: Sales by Geography 2013

Enquiry Before Buy